Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
1. FDA has cleared Dexcom G7 for adults with diabetes. 2. G7 promises improved glucose monitoring with MARD of 8.0%.
FAQ
Why Very Bullish?
FDA approval enhances DXCM's market position and likelihood of increased sales. Historically, such approvals have positively impacted stock prices.
How important is it?
FDA approvals are pivotal for medical companies, significantly impacting stock valuation. This particular approval could solidify DXCM's leadership in CGM technology.
Why Long Term?
The G7's features may drive sustained demand, boosting DXCM's revenue over time.